The DEA and HHS Delay Telehealth Buprenorphine Prescribing Rule Again

The Drug Enforcement Administration (DEA) and the Department of Health and Human Services (HHS) have once again delayed the implementation of a final rule that expands telehealth prescribing of buprenorphine, a key medication used to treat opioid use disorder (OUD). The regulation, which was initially set to take effect earlier this year, has now been pushed back to Dec. 31, 2025. This decision, while allowing more time for regulatory review, adds another layer of uncertainty for healthcare providers and patients who rely on telehealth services for access to treatment. 

The Rule in Question 

The delayed rule permits DEA-registered clinicians to prescribe up to a six-month supply of buprenorphine via telehealth without requiring an in-person visit. This regulatory change was intended to address the growing demand for remote addiction treatment, particularly for individuals in underserved or rural areas who struggle to access in-person care. 

A separate but related regulation affecting the Department of Veterans Affairs (VA) was also postponed. This rule would have allowed VA healthcare providers to prescribe controlled substances without conducting an in-person evaluation, provided that another VA practitioner had already completed one. 

Why the Delay? 

Both rules were finalized in January 2025, shortly before President Donald Trump’s second term began. However, they were initially delayed due to an executive order that froze agency regulatory work pending review. Now, the rules have been postponed again, with the DEA citing the need for further assessment of “questions of fact, law, and policy.” 

The delay has significant implications. On one hand, it maintains the status quo, meaning that current telehealth flexibilities for controlled substance prescribing will remain in place. On the other hand, it extends uncertainty for providers and patients who have been expecting a more permanent framework for telehealth prescribing of buprenorphine. 

The Role of Telehealth in Opioid Use Disorder Treatment 

The opioid crisis continues to be a public health emergency in the United States, with nearly 107,000 drug overdose deaths reported in 2023, according to the CDC. Buprenorphine, a partial opioid agonist, is a crucial medication for opioid use disorder, helping to reduce cravings and withdrawal symptoms. Access to this medication via telehealth has been a lifeline for many patients, particularly during the COVID-19 pandemic when in-person visits were not always possible. 

During the public health emergency, regulators implemented temporary flexibilities that allowed clinicians to prescribe buprenorphine without requiring an in-person appointment. These flexibilities were initially set to expire in 2023 but have been extended multiple times, most recently in November 2024, when they were preserved through 2025. However, the lack of a permanent telehealth prescribing policy has created ongoing challenges for both providers and patients. 

The Ongoing Debate: Access vs. Oversight 

The DEA and HHS face a delicate balancing act. On one side are telehealth advocates and addiction specialists who argue that expanding virtual access to buprenorphine is essential to combating the opioid epidemic. On the other side are concerns about potential misuse and diversion of controlled substances, which have led regulatory agencies to proceed cautiously. 

When the DEA initially proposed its telehealth prescribing rule, it included some restrictions on the number of Schedule II prescriptions that could be provided via telehealth. The agency has maintained that its goal is to protect patient access while preventing the improper dispensing of medications. However, critics argue that additional restrictions could make it more difficult for patients to receive the treatment they need, particularly in areas with few in-person addiction treatment options. 

Impact on Healthcare Providers 

For healthcare providers, the repeated delays and regulatory uncertainty create operational and logistical challenges. Many clinicians have built their addiction treatment programs around telehealth models, and the lack of a clear, long-term policy makes it difficult to plan for the future. 

Telehealth platforms and addiction treatment organizations have been vocal in their concerns about the impact of regulatory instability. The unpredictability of telehealth policies can discourage investment in virtual care infrastructure, disrupt continuity of care, and ultimately harm patients who rely on remote treatment options. 

The Bigger Picture: Telehealth Policy in Flux 

The delayed buprenorphine prescribing rule is part of a broader trend of regulatory uncertainty surrounding telehealth policies in the U.S. Beyond addiction treatment, other telehealth regulations have faced similar setbacks and last-minute extensions. 

For example, in March 2025, Congress extended Medicare’s telehealth coverage flexibilities for only six months, just weeks before they were set to expire. This short-term extension followed another temporary reprieve enacted in December 2024. Healthcare organizations have criticized this piecemeal approach, arguing that it creates instability and hinders the long-term adoption of telehealth services. 

What’s Next? 

With the next deadline set for Dec. 31, 2025, stakeholders in the healthcare industry will be closely watching how the DEA and HHS proceed. The agencies have indicated that they need additional time to review the regulations, but it remains unclear whether they will ultimately make the telehealth prescribing rules permanent or introduce new restrictions. 

In the meantime, telehealth advocates, addiction treatment providers, and policymakers are likely to continue pushing for a more definitive solution. The goal is to ensure that patients with opioid use disorder have reliable, ongoing access to the medications they need while addressing concerns about oversight and drug diversion. 

The repeated delays in finalizing the telehealth buprenorphine prescribing rule highlight the complex intersection of healthcare access, regulatory oversight, and public health policy. While the temporary extension maintains current telehealth prescribing flexibilities, the lack of a permanent solution leaves providers and patients in a state of uncertainty. 

As the opioid crisis continues to devastate communities across the country, ensuring access to effective treatment should remain a top priority. Policymakers must strike a balance between protecting public health and preventing misuse while ensuring that patients in need are not left behind. The coming months will be crucial in determining the future of telehealth addiction treatment in the U.S., and stakeholders must remain engaged in advocating for policies that support both patient care and provider efficiency.